Roche Anvitin (Beva pearl monoantigen anti-injection) glioblastoma adaptation was approved.

Glioblastoma is the most common and malignant primary intracranial tumor in adults.
The 2017 China Cancer Registry Annual Report shows that the incidence of brain tumors in China is 761 per 100,000, of which glioblastoma accounts for 46.1% of malignant brain tumors, the annual incidence rate is about 2.8 per 100,000, with high morbidity, high recurrence rate, high mortality rate and low cure rate, is considered to be one of the most difficult tumors in neurosurgery.
common symptoms of cerebral edema and intracranial pressure increase during the treatment of cerebral glioma, corticosteroid hormones are used to treat the disease accordingly.
but the use of corticosteroid hormones in large doses can lead to high blood pressure, osteoporosis, stomach ulcers and other side effects, resulting in a further decline in the patient's immunity, to a large extent affecting the quality of life of patients.
Avivitin® (Beva Beva Bead monoantigen injection) was approved for the treatment of adult relapsed glioblastoma based primarily on a multi-center, open-label, randomized controlled critical Phase III clinical trial EORTC 26101.
the results confirmed that treatment based on anvirtin ® (beva bead monoantigen injection) extended the time of disease-free progression or death compared to chemotherapy alone (medium PFS: 4.2 months vs. 1.5 months, HR=0.52, 95% CI: 0.41-0.64), reducing the risk of disease progression by 51%.
patients with disease remission showed more stable global health scores and cognitive function than non-remissioners during the progression-free lifetime.
beva bead monoantigen is one of the most important therapeutic drugs in the treatment of glioblastoma after tymoxamine.
As a recommended therapy for patients with relapsed glioblastoma,
has been included in the guidelines and consensus at home and abroad, including NCCN, ESMO, National Health And Wellness Commission "Guidelines for diagnosis and treatment of gliomas", China's central nervous system glioma targeted immunity and electric field therapy expert consensus, etc., has also been approved for the treatment of glioblastoma in more than 80 countries and regions such as the United States, Switzerland, Japan, Korea.
.